chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. aiming to be a healthcare group with a global presence, fosun pharma, established in shanghai in 1994, has built its core business around innovative drug r&d and manufacturing.
innovation for health — the fourth hongqiao international health technology innovation forum held in shanghai
on november 6, 2021, as a parallel supporting event of the 4th china international import expo (ciie), the 4th hongqiao international health technology innovation forum with the theme of "innovation for good health" was successfully held. this forum was sponsored by the international health exchange and cooperation center nhc prc (ihecc) and china pharmaceutical innovation and research development association,
2021 csco | henlius publishes newest phase ii clinical data of novel anti-pd-1 mab serplulimab for treatment of advanced cervical cancer
in this meeting, henlius releases phase 2 study results of serplulimab (hlx10, novel anti-pd-1 antibody), in patients with advanced cervical cancer in an oral presentation.
2021 csco | henlius publishes phase iii clinical data of bevacizumab biosimilar hlx04 for treatment of metastatic colorectal cancer
in this meeting, henlius releases phase 3 study results of hlx04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
guided by innovation and internationalization, fosun pharma increases its investment in r&d and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its r&d and clinical trial capacities for new drugs, and speeds up the r&d and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent r&d, co-development, in-licensing, and in-depth incubation.
major drug projects under development
as of december 31, 2021, fosun pharma had more than 240 projects under development, including innovator drugs, biosimilars, generic drugs and consistency evaluation.
- self-developed small molecule innovator drugs
- self-developed innovative biologics
- licensed-in innovator drugs
- self-developed biosimilars
- consistency evaluation projects